Nitidine chloride inhibits renal cancer cell metastasis via suppressing AKT signaling pathway

Food and Chemical Toxicology

Volumn 60, Issue , 2013, Pages 246-251

  Fang, Zhiqing ^a   Tang, Yueqing ^a   Jiao, Wei ^a   Xing, Zhaoquan ^a   Guo, Zhaoxin ^a   Wang, Weichang ^a   Shi, Benkang ^a   Xu, Zhonghua ^a   Liu, Zhaoxu ^a,b  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

AKT; Metastasis; MMP; Nitidine chloride; Renal cancer

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GELATINASE A; GELATINASE B; NITIDINE; PROTEIN KINASE B;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL MIGRATION; CONTROLLED STUDY; DRUG DETERMINATION; DRUG POTENCY; DRUG POTENTIATION; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; INTRACELLULAR SIGNALING; KIDNEY METASTASIS; METASTASIS INHIBITION; TUMOR INVASION;

AKT; AKT/PKB; DIMETHYLSULFOXIDE; DMEM; DMSO; DULBECCO'S MODIFIED EAGLE'S MEDIUM; FBS; FETAL BOVINE SERUM; MATRIX METALLOPROTEINASE; METASTASIS; MMP; NITIDINE CHLORIDE; PBS; PBST; PHOSPHATE BUFFERED SALINE; PHOSPHATE BUFFERED SALINE AND TWEEN 20; RAC-ALPHA SERINE/THREONINE-PROTEIN KINASE; RENAL CANCER;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BENZOPHENANTHRIDINES; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; HUMANS; KIDNEY NEOPLASMS; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; NEOPLASM METASTASIS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84882743499     PISSN: 02786915     EISSN: 18736351     Source Type: Journal    
DOI: 10.1016/j.fct.2013.07.062     Document Type: Article

References (32)

1. Ahmad N., Wang W., Nair R., Kapila S. Relaxin induces matrix-metalloproteinases-9 and -13 via RXFP1: induction of MMP-9 involves the PI3K, ERK, Akt and PKC-zeta pathways. Molecular and Cellular Endocrinology 2012, 363:46-61.
2. Baaten G., Voogd A.C., Wagstaff J. A systematic review of the relation between interleukin-2 schedule and outcome in patients with metastatic renal cell cancer. European Journal of Cancer 2004, 40:1127-1144.
3. Blume-Jensen P., Hunter T. Oncogenic kinase signalling. Nature 2001, 411:355-365.
4. Brugge J., Hung M.C., Mills G.B. A new mutational AKTivation in the PI3K pathway. Cancer Cell 2007, 12:104-107.
5. Chen J., Wang J., Lin L., He L., Wu Y., Zhang L., Yi Z., Chen Y., Pang X., Liu M. Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer. Molecular Cancer Therapeutics 2012, 11:277-287.
6. Del Poeta M., Chen S.F., Von Hoff D., Dykstra C.C., Wani M.C., Manikumar G., Heitman J., Wall M.E., Perfect J.R. Comparison of in vitro activities of camptothecin and nitidine derivatives against fungal and cancer cells. Antimicrobial Agents and Chemotherapy 1999, 43:2862-2868.
7. Fang Z., Tang Y., Fang J., Zhou Z., Xing Z., Guo Z., Guo X., Wang W., Jiao W., Xu Z., Liu Z. Simvastatin inhibits renal cancer cell growth and metastasis via AKT/mTOR, ERK and JAK2/STAT3 pathway. PloS One 2013, 8:e62823.
8. Fresno Vara J.A., Casado E., de Castro J., Cejas P., Belda-Iniesta C., Gonzalez-Baron M. PI3K/Akt signalling pathway and cancer. Cancer Treatment Reviews 2004, 30:193-204.
9. Gialeli C., Theocharis A.D., Karamanos N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. The FEBS Journal 2011, 278:16-27.
10. Gore M.E., Griffin C.L., Hancock B., Patel P.M., Pyle L., Aitchison M., James N., Oliver R.T., Mardiak J., Hussain T., Sylvester R., Parmar M.K., Royston P., Mulders P.F. Interferon alfa-2a versus combination therapy with interferon alfa-2a, interleukin-2, and fluorouracil in patients with untreated metastatic renal cell carcinoma (MRC RE04/EORTC GU 30012): an open-label randomised trial. Lancet 2010, 375:641-648.
11. Gupta K., Miller J.D., Li J.Z., Russell M.W., Charbonneau C. Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): a literature review. Cancer Treatment Reviews 2008, 34:193-205.
12. Himelstein B.P., Lee E.J., Sato H., Seiki M., Muschel R.J. Tumor cell contact mediated transcriptional activation of the fibroblast matrix metalloproteinase-9 gene: involvement of multiple transcription factors including Ets and an alternating purine-pyrimidine repeat. Clinical & Experimental Metastasis 1998, 16:169-177.
13. Horiguchi A., Oya M., Uchida A., Marumo K., Murai M. Elevated Akt activation and its impact on clinicopathological features of renal cell carcinoma. The Journal of Urology 2003, 169:710-713.
14. Hu Y., Ivashkiv L.B. Costimulation of chemokine receptor signaling by matrix metalloproteinase-9 mediates enhanced migration of IFN-alpha dendritic cells. Journal of Immunology 2006, 176:6022-6033.
15. Hu J., Zhang W.D., Liu R.H., Zhang C., Shen Y.H., Li H.L., Liang M.J., Xu X.K. Benzophenanthridine alkaloids from Zanthoxylum nitidum (Roxb.) DC, and their analgesic and anti-inflammatory activities. Chemistry & Biodiversity 2006, 3:990-995.
16. Kallakury B.V., Karikehalli S., Haholu A., Sheehan C.E., Azumi N., Ross J.S. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2001, 7:3113-3119.
17. Kosmidou I., Xagorari A., Roussos C., Papapetropoulos A. Reactive oxygen species stimulate VEGF production from C(2)C(12) skeletal myotubes through a PI3K/Akt pathway. American Journal of Physiology Lung Cellular and Molecular Physiology 2001, 280:L585-592.
18. Kuroda K., Horiguchi A., Sumitomo M., Asano T., Ito K., Hayakawa M. Activated Akt prevents antitumor activity of gefitinib in renal cancer cells. Urology 2009, 74:209-215.
19. Laird A., O'Mahony F.C., Nanda J., Riddick A.C., O'Donnell M., Harrison D.J., Stewart G.D. Differential expression of prognostic proteomic markers in primary tumour, venous tumour thrombus and metastatic renal cell cancer tissue and correlation with patient outcome. PloS One 2013, 8:e60483.
20. Lam J.S., Shvarts O., Leppert J.T., Figlin R.A., Belldegrun A.S. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. The Journal of Urology 2005, 173:1853-1862.
21. Liao J., Xu T., Zheng J.X., Lin J.M., Cai Q.Y., Yu D.B., Peng J. Nitidine chloride inhibits hepatocellular carcinoma cell growth in vivo through the suppression of the JAK1/STAT3 signaling pathway 2013, International Journal of Molecular Medicine.
22. Lv P., Huang K., Xie L., Xu X. Palladium-catalyzed tandem reaction to construct benzo[c]phenanthridine: application to the total synthesis of benzo[c]phenanthridine alkaloids. Organic & Biomolecular Chemistry 2011, 9:3133-3135.
23. Pal I., Mandal M. PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacologica Sinica 2012, 33:1441-1458.
24. Pan X., Han H., Wang L., Yang L., Li R., Li Z., Liu J., Zhao Q., Qian M., Liu M., Du B. Nitidine chloride inhibits breast cancer cells migration and invasion by suppressing c-Src/FAK associated signaling pathway. Cancer Letters 2011, 313:181-191.
25. Qian J., Zou Y., Rahman J.S., Lu B., Massion P.P. Synergy between phosphatidylinositol 3-kinase/Akt pathway and Bcl-xL in the control of apoptosis in adenocarcinoma cells of the lung. Molecular Cancer Therapeutics 2009, 8:101-109.
26. Rabinovitch R.A., Zelefsky M.J., Gaynor J.J., Fuks Z. Patterns of failure following surgical resection of renal cell carcinoma: implications for adjuvant local and systemic therapy. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 1994, 12:206-212.
27. Schrader A.J., Hofmann R. Metastatic renal cell carcinoma: recent advances and current therapeutic options. Anti-Cancer Drugs 2008, 19:235-245.
28. Srinivasan S., Koduru S., Kumar R., Venguswamy G., Kyprianou N., Damodaran C. Diosgenin targets Akt-mediated prosurvival signaling in human breast cancer cells. International Journal of Cancer. Journal International du Cancer 2009, 125:961-967.
29. Tong B., Lu D., Wei Z., Wang T., Xia Y., Dai Y. Gleditsioside B, a triterpene saponin isolated from the anomalous fruits of Gleditsia sinensis Lam., abrogates bFGF-induced endothelial cell migration through preventing the activation of MMP-2 and FAK via inhibiting ERK and PI3K/AKT signaling pathways. Vascular Pharmacology 2013, 58:118-126.
30. Vogelzang N.J., Stadler W.M. Kidney cancer. Lancet 1998, 352:1691-1696.
31. Wu B., Dong B., Xu Y., Zhang Q., Shen J., Chen H., Xue W. Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PloS One 2012, 7:e32530.
32. Zhou Q.L., Yang C.X., Liang H., Liu H.Z., Wang H.B., Liu Y., Lai X.H., Gu M.N. Propofol reduces MMPs expression by inhibiting PI3K/AKT activity in human HepG2 cells. Biomedicine & Pharmacotherapy=Biomedecine & Pharmacotherapie 2013.